Showing results (211-220 of 296) with videos related to
Sort By:
Pageof 30
The Lancet. Oncology|December 20, 2014
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 studyMax S Topp, Nicola Gökbuget, Anthony S Stein, et al.Blood|October 2, 2012
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALLMax S Topp, Nicola Gökbuget, Gerhard Zugmaier, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 StudyMichael Wang, Javier Munoz, Andre Goy, et al.Nature Medicine|February 23, 2021
Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myelomaMatteo C Da Vià, Oliver Dietrich, Marietta Truger, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2019
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study GroupMichael Fuchs, Helen Goergen, Carsten Kobe, et al.Blood Cancer Journal|July 30, 2025
Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvementMaximilian J Steinhardt, Christoph Schaefers, Lisa B Leypoldt, et al.The New England Journal of Medicine|March 2, 2017
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic LeukemiaHagop Kantarjian, Anthony Stein, Nicola Gökbuget, et al.Journal of the American College of Cardiology|November 17, 2024
Treating Older Patients in Cardiogenic Shock With a Microaxial Flow Pump: Is it DANGERous?Anika Klein, Rasmus P Beske, Christian Hassager, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 18, 2011
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survivalMax S Topp, Peter Kufer, Nicola Gökbuget, et al.Circulation|October 27, 2024
Microaxial Flow Pump Use and Renal Outcomes in Infarct-Related Cardiogenic Shock: A Secondary Analysis of the DanGer Shock TrialElric Zweck, Christian Hassager, Rasmus P Beske, et al.Pageof 30